Literature DB >> 11992846

Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation.

José M Martínez-Jabaloyas1, José L Ruiz-Cerdá, Miguel Hernández, Ana Jiménez, Fernando Jiménez-Cruz.   

Abstract

OBJECTIVES: To assess the prognostic value of flow cytometry and nuclear morphometry in prostate cancer after androgen deprivation treatment.
METHODS: A total of 127 patients with a prostate cancer diagnosis who had undergone androgen suppression were retrospectively studied. The DNA content by flow cytometry and nuclear morphometry was studied from biopsy specimens. In the patients with Stage M0, two multivariate analyses by the Cox proportional regression model were performed to determine whether the experimental variables (DNA content and nuclear area) added independent information to the classic prognostic factors (Gleason score and stage). Using the statistical analysis results, risk groups were created.
RESULTS: T and M categories, Gleason score, DNA ploidy, and mean nuclear area proved to have prognostic value in the univariate analysis. For the group of patients free of metastasis (M0), it was possible to create low, intermediate, and high-risk groups using stage and Gleason score with statistically significant differences in survival. Multivariate analysis, combining the classic and experimental variables, selected Gleason score and DNA content as prognostic independent factors. Also, risk groups with statistically significant differences in survival were created. However, the net result of combining both kinds of factors was at least as valuable as the combination of stage and Gleason score in predicting survival.
CONCLUSIONS: The determination of DNA ploidy and mean nuclear area do not add enough independent information to improve the predictive value to justify their use in this group of patients treated with hormonal therapy.

Entities:  

Mesh:

Year:  2002        PMID: 11992846     DOI: 10.1016/s0090-4295(02)01530-3

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

1.  Oestrogen supplementation following castration promotes stromal remodelling and histopathological alterations in the Mongolian gerbil ventral prostate.

Authors:  Wellerson Rodrigo Scarano; Daniel Emídio de Sousa; Silvana Gisele Pegorin Campos; Lara Silvia Corradi; Patricia Simone Leite Vilamaior; Sebastião Roberto Taboga
Journal:  Int J Exp Pathol       Date:  2007-11-10       Impact factor: 1.925

2.  Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.

Authors:  Sumit Isharwal; Michael Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

Review 3.  Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.

Authors:  Håvard E Danielsen; Manohar Pradhan; Marco Novelli
Journal:  Nat Rev Clin Oncol       Date:  2015-11-24       Impact factor: 66.675

4.  Age-related histopathological lesions in the Mongolian gerbil ventral prostate as a good model for studies of spontaneous hormone-related disorders.

Authors:  Silvana Gisele Pegorin Campos; Cristiani Zanetoni; Wellerson Rodrigo Scarano; Patrícia Simone Leite Vilamaior; Sebastião Roberto Taboga
Journal:  Int J Exp Pathol       Date:  2008-02       Impact factor: 1.925

5.  TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy.

Authors:  Anuradha Gopalan; Margaret A Leversha; Jaya M Satagopan; Qin Zhou; Hikmat A Al-Ahmadie; Samson W Fine; James A Eastham; Peter T Scardino; Howard I Scher; Satish K Tickoo; Victor E Reuter; William L Gerald
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

6.  Quantitative pathology: historical background, clinical research and application of nuclear morphometry and DNA image cytometry.

Authors:  Abdelbaset Buhmeida
Journal:  Libyan J Med       Date:  2006-09-20       Impact factor: 1.657

7.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.